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Abstract Metabolic control improves outcomes
associated with mucormycosis. The aim of this study
was to compare the in vitro proliferation of Rhizopus
oryzae in blood of individuals with and without
diabetes at different glycaemic levels. Ninety-five
individuals were included. Blood samples from each
participant were incubated with sporangiospores of R.
oryzae. The germination, filamentation and growth of
R. oryzaewere compared at different time points. Four
groups were defined, one without (group A, n = 30)
and three with diabetes: group B (HbA1c B7%,
N = 24), group C (HbA1c 7.1–9%, N = 20) and
group D (HbA1c[ 9%, N = 21). The percentage of
germinated sporangiospores was higher in the group A
after 6 h (group A 56% ± 3, group B 35% ± 4, group
C 48% ± 4, group D 46% ± 1.4, p = 0.01), 12 h
(group A 54% ± 1.4, group B 19% ± 4, group C
16% ± 1, group D 9.5% ± 5, p\ 0.001) and 24 h
(group A 29% ± 1, group B 12% ± 4, group C
13.5% ± 3.5, group D 12% ± 1, p\ 0.01). The
filamentation was higher in groups with diabetes.
Group B showed higher filamentation grade than
group A at 6 h (0.4 ± 0.04 vs 1 ± 0.09, p\ 0.001)
and 24 h (1.6 ± 0.05 vs 2.1 ± 0.1, p = 0.05). In
conclusion, R. oryzae proliferation was higher among
diabetic individuals, including good glycaemic con-
trol, than among non-diabetic individuals.
Keywords Mucormycosis Diabetes  Proliferation 
Germination  Rhizopus oryzae
Introduction
The principal agent causing mucormycosis is Rhizopus
oryzae. Mucormycosis is a lethal fungal infection
affecting mainly individuals with diabetes, individuals
with haematologicalmalignancies [1–4] and individuals
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with trauma [5, 6]. Chronic and acute forms of
glycaemic uncontrolled diabetes have been described
as main risk factors in the development of mucormy-
cosis [7–10], and this is due to the role of glucose in
modulating angioinvasion [11]. Metabolic control has
shown to decrease the susceptibility to mucormycosis
and to improve the survival rate associated with this
infection in animal models [12, 13]. Also, it has been
highlighted, by clinical guidelines and experts in the
field, thatmetabolic control is an essential component in
the management of mucormycosis when it affects
diabetic populations [14, 15]. In general, one of the
recommendations in metabolic control of diabetes is to
get a target of glycosylated haemoglobin (HbA1c)\7%
[16]. Hence, the aim of this study was to compare the
in vitro proliferation of R. oryzae in blood of individuals
with andwithout diabetes.Our results showed lesser and
slower in vitro proliferation of R. oryzae in samples of
diabetic individuals and good glycaemic control in
comparison with uncontrolled counterparts; however, it
was still higher than the individuals without diabetes.
Materials and Methods
Included Population and Blood Samples
This project was approved by the local IRB at Hospital
General Dr Manuel Gea Gonza´lez with the number
36-55-2015. The selection of participants was based
on their previously programmed hospital check-up
appointments and the period of time when this study
was held. During this period, 1505 individuals were
identified as potential participants but only 141 had
programed an appointment for HbA1c test. Finally, 95
individuals were included, and blood samples and
clinical data were obtained. After a revision of medical
records to confirm the diabetes status of the selected
individuals (the diagnosis of diabetes was done
independently by the healthcare provider/physician
as part of a regular standard of care), they were
categorised into groups with and without diabetes and
by HbA1c level, as shown in Fig. 1.
One blood sample was drawn from each participant
in tube without anticoagulant (SST BD Vacutainer).
All samples were subject to mechanical and freezing
cellular lysis. Mechanical cellular lysis consisted of
vortexing the sample for 5 min; meanwhile, freezing
cellular lysis consisted of storing the samples at
-70 C until their use for further in vitro assays.
Strains and Culture
During the in vitro assays, a respiratory clinical isolate
of R. oryzae was used. This isolate was identified by
conventional methods and sequencing. Conventional
methods consisted of morphology identification of
colony and microscopy using lactophenol cotton blue
stain. ITS1-2 regions were amplified and sequenced
using the universal primers ITS1/ITS4 previously
published elsewhere [17], nucleotide sequence acces-
sion number MF379466.
The R. oryzae strain was cultured and maintained in
Sabouraud dextrose agar (SDA) for five days at 30 C.
Following the CLSIM38A guidelines, sporangiospores
suspension was collected to obtain a solution at 0.5
McFarland corresponding to 105 sporangiospores/mL.
Ninety-five sporangiospores suspensions from the same
strain, one for each participant, were collected. Spo-
rangiospores suspensions were kept frozen at -70 C
until their further use.
Design of the Assay
For in vitro interaction assays, after thawing each
blood sample and sporangiospores, 500 ll of blood of
each participant and 500 ll of sporangiospores sus-
pension (a dilution 1:2) were mixed and incubated at
30 C. Each assay was performed in duplicate.
Definitions
The growth of R. oryzae was evaluated at the time of
the inoculation (time 0), and at 3, 6, 12 and 24 h of
incubation. Observations were made in the same way
for each one of the 95 samples. These observations
were as follows: 1) number of sporangiospores and
germination rate per mL, 2) filamentation/hyphae
formation and 3) growth in Sabouraud dextrose agar
(SDA). The number of sporangiospores was estimated
per mL using a haemocytometer, and germination rate
was estimated dividing the elongated sporangiospores
by the total number of sporangiospores. To evaluate
the filamentation, 10 ll of the sample on slide with
40% KOH solution was observed using light micro-
scopy at 409 objective. The grade of filamentation
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was evaluated as follows: 1) Grade 1: 1–100 hyphae
observed per 100 fields, 2) Grade 2: 101–200 hyphae
per 100 observed fields and 3) Grade 3:[200 hyphae
per 100 observed fields. SDA growth was measured in
millimetres after culturing 10 ll of each sample in a
SDA after 12 h of incubation, as shown in Fig. 2.
Statistical Analysis
Results are presented as proportions and/or median or
mean values (mean corresponding to the duplicated
assays) as required. Comparisons were made with
Kruskal–Wallis, one-way ANOVA, Fisher’s LSD and
Dunnett’s tests as appropriate. P value B 0.05 was
considered statistically significant when two groups
were compared and p value B 0.01 when four groups
were compared between them. Statistical tests were
performed using SPSS Inc 24 software (IBM Corpo-
ration, New York, USA).
Results
The 95 individuals included in this study were
categorised depending on the HbA1c level. The
categorisation was made after all in vitro assays were
performed to be blind during the assay.
Clinical Characteristics Between Groups were
not Statistically Different Except for Glycaemic
Control
Age, statin use, biochemical parameters (such as
creatinine levels and haematic cytometry), except
1505 elegible individuals
141 programmed for  HbA1c 
test
Without 
diabetes
Group A. N=30 
HbA1c 7%
Diabetes
Group B. N=24 
HbA1c 7%
Group C. N=20  
HbA1c 7.1-9%
Group D. N=21 
HbA1c >9
Excluded due to infection, prior use of 
antibiotic, renal disease neutropenia, anaemia, 
prior transfusion, age <18 years or did not 
acepted to participate. N=36
Fig. 1 Study design and categories of the study groups. The
selection of the participants was done based on previously
check-up appointments, and they had to have a HbA1c test
programmed. The study groups were categorised depending on
the HbA1c levels, group A: individuals without diabetes,
individuals with diabetes were group B (HbA1c B7%), group
C (HbA1c 7.1–9%), group D (HbA1c[ 9%)
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fasting glucose and HbA1c, were not significantly
different between groups as given in Table 1. Only
fasting glucose and HbA1c were different between
groups (p\ 0.05). The highest fasting glucose value
was 456 g/dL and was found in one subject in group D.
Acute hyperosmolar state was ruled out in this subject.
Levels of HbA1c were B7% for groups A and B
(median, minimum–maximum values 5.7, 4–6.4% vs
6.45, 5.3–7%) and for group C and group D[ 7.1
(median, minimum–maximum values 8, 7.1–8.9% vs
10.8, 9.3–15.3%).
In vitro Germination Process Started Earlier in all
Groups with Diabetes but Lasts Longer
in the Group Without Diabetes
The number of sporangiospores at the beginning of the
assay between groups (254 vs 306 vs 334 vs 341,
p = 0.21) decreased after 3 h of incubation (Fig. 3).
Differences in the decreasing number of sporan-
giospores were evident between the group without
diabetes compared with the groups with diabetes after
6 h of incubation (group A 111 ± 2.1 vs group B
62 ± 5.6, group C 36 ± 9.8, group D 41 ± 5,
p\ 0.001). In groups C and D with diabetes, levels
of HbA1c between 7.1–9% and[9%, respectively, the
number of sporangiospores did not differ between
them (group C 36 ± 9.8 vs group D 41 ± 5, p = 0.8);
however, the number of sporangiospores in these
groups decreased higher and faster than in the group B
with HbA1c level in glycaemic control
(HbA1c\ 7%). After 6 h of incubation, between
groups A (without diabetes) and B, the decrease in
sporangiospores was statistically different (group A
111 ± 2.1 vs group B 62 ± 5.6, p = 0.005) even
when both groups had levels of HbA1c\ 7%. It was
evident that the decreasing number of sporangiospores
corresponded to the starting of the germination
process. The percentage of germinated sporan-
giospores was higher in the group A (without diabetes)
after 6 h (group A 56% ± 3 vs group B 35% ± 4,
group C 48% ± 4, group D 46% ± 1.4, p = 0.01),
Fig. 2 Definitions of the variables used to evaluate in vitro
growth of R. oryzae in this study. a Number of sporangiospores
per mL (Magnification 940), b germination rate (elongated
bodies per total of sporangiospores seen per mL, magnification
940), c grade of filamentation/hypha formation per 100 fields
(0 = no hyphae in 100 fields, ? = 1–100 hyphae in 100 fields,
?? = 101–200 hyphae in 100 fields, ??? = more than 201
hyphae in 100 fields); magnification 9240, d growth in SDA
measured in Mm. Sporangiospores and germinated bodies were
counted using an haemocytometer
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12 h (group A 54% ± 1.4, group B 19% ± 4, group C
16% ± 1, group D 9.5% ± 5, p\ 0.001) of incuba-
tion and was maintained until 24 h (group A 29% ± 1,
group B 12% ± 4, group C 13.5% ± 3.5, group D
12% ± 1, p\ 0.01), as shown in Fig. 4. The more
evident germination difference between groups with
and without diabetes was at 12 h of incubation, as
shown in Table S1. The lower germination rate in
groups with diabetes was due to the faster hyphae
formation.
The Grade of Filamentation in vitro of R. oryzae
was Higher in all Groups with Diabetes Including
Those with Glycaemic Control when Compared
with the Group Without Diabetes
The grade of filamentation was higher and faster in all
groups with diabetes compared with the group without
diabetes after 3 h of incubation (Fig. 4). The group B
(with diabetes and HbA1c B7%) showed higher and
faster grade of filamentation than individuals without
diabetes at 6 h (group A 0.4 ± 0.04 vs group B
1 ± 0.09, p\ 0.001) and 24 h (group A 1.6 ± 0.05
vs group B 2.1 ± 0.1, p\ 0.05) (Fig. 5). All groups
with diabetes had higher filamentation grade than the
group A, as shown in Table S2. Between all the
diabetes groups, the grade of filamentation was higher
for groups B and C, as shown in Table S3. Also, when
mycelial growth was evaluated in SDA, groups with
diabetes initiated the growth faster than the group
without diabetes at 3 h (group A 1 mm ± 0.14, group
B 3 mm ± 0.09, group C 2.3 mm ± 0.17, group D
2.23 mm ± 0.13, p\ 0.001). After 3 h of incubation
on SDA, the growing was similar between groups
being the group D the one with higher and faster
growing out of all the other groups (Table 2).
Finally, to rule out if the R. oryzae growth was
influenced by the use of statins, a statistical analysis of
all the growing characteristics was performed and no
differences were found (Table S4). On the other hand,
it was noted that R. oryzae germination and filamen-
tation were higher when fasting glucose levels were
higher than 200 g/dL (Table S5), and these levels were
found only in groups C (HbA1c levels between 7.1 and
9%) and D (HbA1c[ 9%) with diabetes (Fig. 5).
Discussion
This study describes that the beginning of filamenta-
tion process in R. oryzae depends on the length of
germination process. In samples of the group without
0
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GROUP A GROUP B HBA1C<7 GROUP C HBA1C 7-9 GROUP D HBA1C >9
*
Fig. 3 Number of
sporangiospores during the
period of observation. Plot
showing the results
presented as mean and
standard deviation obtained
from the duplicated
experiments. N = 95. One-
way ANOVA, *p\ 0.01.
Group A: individuals
without diabetes. Groups B
(HbA1c B7%), C
(HbA1c = 7.1–9%) and D
(HbA1c[ 9%): individuals
with diabetes. The decrease
in number of
sporangiospores
corresponds to the start of
the germination process
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diabetes, germination period was longer, reflecting
that the hyphae were developed after a longer period;
meanwhile, filamentation process started earlier in
blood samples of groups with uncontrolled diabetes.
Interestingly, in the controlled diabetic group, the
filamentation grade was lower than in the uncontrolled
diabetic groups but significantly higher when com-
pared with the non-diabetes group.
The higher growth capacity of R. oryzae in samples
of individuals with diabetes could be explained by
high concentrations of glucose and iron being the main
factors favouring the germination and fungal invasion
of R. oryzae [10, 18]. Iron exists in two states, Fe2?
(ferrous) or Fe3? (ferric), and the latest state is
insoluble which limits its transport to the fungal
intracellular compartment [18]. Iron is essential for R.
oryzae growth, this pathogen has developed mecha-
nisms to improve the assimilation of iron such as
ferritins to store it, internal and external siderophores,
and reductase/permease systems to improve iron
uptake, and also iron can be obtained by R. oryzae
from host haemoglobin [19]. In individuals with
diabetic ketoacidosis, it is known that low pH
promotes the release of iron [13]; however, hypergly-
caemia, by itself, also promotes the damage of iron-
sequestering proteins such as haemoglobin causing the
releasing of serum-free iron [20]. In this study, none of
the individuals had diabetic ketoacidosis although
individuals with high HbA1c had also higher fasting
glucose levels, meaning the main factor for the higher
fungal growing was due to high levels of glucose, and
probably the secondary releasing of iron due to
hyperglycaemia.
The GRP78 protein has been previously reported
as the receptor for CotH3 ligand in R. oryzae [21],
allowing the interactions between the host and fungi.
The expression of GRP78 protein is promoted by
high concentrations of glucose, iron and acidotic
environments [18]. The overexpression of GRP78
protein leads to higher rates of endocytosis and
cellular damage allowing the invasion, injury and
dissemination of R. oryzae. In our study, the cells
were lysed and therefore it could not be said that the
higher concentration of GRP78 protein is playing a
role in the higher growth rates of R. oryzae in diabetic
groups.
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Fig. 4 Germination rate
during the period of
observation. Plot showing
the results presented as
mean and standard deviation
obtained from the duplicated
experiments. N = 95, One-
way ANOVA, *p\ 0.01,
**p\ 0.001. Group A:
individuals without
diabetes. Groups B (HbA1c
B7%), C
(HbA1c = 7.1–9%) and D
(HbA1c[ 9%): individuals
with diabetes. Decreasing
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The main observation in this study was that despite
the glycaemic control, diabetic population could still
be at risk of mucormycosis and, hence, have worst
clinical outcomes. Tuberculosis is one example of
disease where glycaemic control decreases the rates of
infection but not at non-diabetic population rates. The
incidence of tuberculosis could be twice higher in
individuals with controlled diabetes compared with
individuals without diabetes [22]. Similar observa-
tions have been also reported for urinary tract
infections [23] and major macrovascular complica-
tions [24].
On the other hand, the role of HbA1c as the best
marker of glycaemic control has been debated because
it correlates with chronic sustained hyperglycaemia
but not with all the acute glucose variability such as
postprandial hyperglycaemia excursions which are
best evaluated with mean amplitude of glycaemic
excursion [25]. This implies that individuals with
controlled diabetes in our study, although having
0
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GROUP A GROUP B HBA1C<7 GROUP C HBA1C 7-9 GROUP D HBA1C >9
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Fig. 5 The grade of
filamentation during the
period of observation. Plot
showing results presented as
mean and standard deviation
obtained from the duplicated
experiments. N = 95. One-
way ANOVA, *p\ 0.001,
** p = 0.005. Grade of
filamentation/hypha
formation per 100 fields
(0 = no hyphae in 100
fields,? = 1–100 hyphae in
100 fields, ?? = 101–200
hyphae in 100 fields,
??? = more than 201
hyphae in 100 fields). Group
A: individuals without
diabetes. Groups B (HbA1c
B7%), C (HbA1c =
7.1–9%) and D
(HbA1c[ 9%): individuals
with diabetes
Table 2 The growth of R. oryzae in Sabouraud dextrose agar
Group (N = 95) 3 h (mm)* 6 h (mm)** 12 h (mm)*** 24 h (mm)
A (n = 30) 1.0 ± 0.14 7.8 ± 0.7 34 ± 0.33 82 ± 0.7
B (n = 24) 3.0 ± 0.09 8.7 ± 0.8 30 ± 2.5 81 ± 2.1
C (n = 20) 2.3 ± 0.17 9.4 ± 0.2 32 ± 0.56 83 ± 0.7
D (n = 21) 2.2 ± 0.13 11.0 ± 0.8 34 ± 0.14 81 ± 1.4
The results are presented as mean and standard deviation obtained from the duplicated experiments. Group A: individuals without
diabetes. Group B (HbA1c B7%), C (HbA1c = 7.1–9%) and D (HbA1c[ 9%) are individuals with diabetes. Mm = millimetres.
P values shown in this table were calculated with Fisher’s LSD test
A versus B, both groups had HbA1c\ 7%, but group A had not diabetes and group B had diabetes, * p = 0.0001, *** p = 0.03
B versus C, groups with diabetes with HbA1c\ 7% versus 7.1–9%, * p = 0.005
B versus D, groups with diabetes with HbA1c\ 7% versus[ 9%, * p = 0.003, **p = 0.02, *** 0.04
C versus D, groups with diabetes with HbA1c 7–9% versus[ 9%, p = NS
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normal fasting glucose levels, could be experiencing
hyperglycaemic postprandial periods in a regular
basis, which are not experienced by non-diabetic
individuals. These hyperglycaemic episodes could be
having indirect effects on releasing of free serum iron,
and therefore, this mechanism would be favouring the
R. oryzae growth in our assays. Unfortunately, the
measurement of free iron was not taken in our study
due to its original design. The impact of this glycaemic
variability has been previously associated with higher
risk of sepsis and mortality in individuals suffering
burns and autologous haematopoietic cell transplant
recipients [26, 27].
The findings in this study require to be studied and
described in greater depth. In the future, interactions
with host will be evaluated by our group using in vitro
and in vivo models. At the authors’ knowledge, this is
the first study reporting individuals with diabetes and
good glycaemic control could still be at higher risk of
mucormycosis than the non-diabetic individuals.
These findings could partially answer and lead to
further research of why more than 50% of the
mucormycosis cases are presented without diabetic
ketoacidosis [2] and why some cases have chronic
evolution, instead of acute presentation [28], without
an apparently associated factor with this clinical
feature.
Conclusion
Individuals with diabetes and good glycaemic control
had lesser and slower in vitro proliferation of R. oryzae
compared with uncontrolled ones; however, it was still
higher than the individuals without diabetes. The main
observation in this study was that despite the gly-
caemic control, diabetic population might have a
higher risk of developing mucormycosis.
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